PROPYLENE GLYCOL FREE MINOXIDIL TOPICAL FORMULATION FOR HAIR LOSS BASED ON PATENTED TECHNOLOGY
|
|
- Jody McCarthy
- 6 years ago
- Views:
Transcription
1 Page 1 of 7 LICENSING OPPORTUNITY PROPYLENE GLYCOL FREE MINOXIDIL TOPICAL FORMULATION FOR HAIR LOSS BASED ON PATENTED TECHNOLOGY NO PROPYLENE GLYCOL NO SCALP IRRITATION, NO GREASY HAIR BIOEQUIVALENT ABSORPTION TRHOUGH THE SKIN COMPARED TO REFERENCE PRODUCTS NO RESIDUAL CRYSTALLINE PRECIPITATE IN SCALP EASY AND COST-EFFECTIVE PRODUCTION AT A COMMERCIAL SCALE INTELLECTUAL PROPERTY RIGHTS UNTIL 2031 THE COMPANY Bionanoplus was founded in 2011 and combines the enthusiasm of a young company with more than 10 years of experience in the nanotechnology and drug delivery fields in academic institutions. Bionanoplus was born in the spirit of avoiding nanoparticles industrial scale-up issues that are decisive factors in many project failures. For this reason, we developed several technology platforms that allow the manufacturing of stable and homogeneous nanoparticles without the use of volatile organic solvents or special equipment, thus ensuring a cost-effectiveness and adequate scalability from lab to final production. In addition, all the materials used in the manufacturing of our nanoparticles compile with the regulatory requirements and are present as common excipients in many pharmaceuticals. The staff of Bionanoplus is formed by 8 people with extensive experience in scientific innovation and intellectual property management. Backing us up are more than 50 research articles in peer-reviewed journals and 6 patents. At the beginning of 2013, Bionanoplus was certified as compliant with the principles of Good Laboratory Practices (GLPs), a new step on the road to excellence on which we are embarked.
2 Page 2 of 7 MINOXIDIL & HAIR LOSS BACKGROUND Minoxidil is the only topical medication approved by the international regulatory agencies for the treatment of hair loss since the early 1990's. Minoxidil is available in both 2% and 5% concentrations and has clinically proven to slow the progression of hair loss and regrow hair after topical application. It is recommended that males use minoxidil 5% whilst females use minoxidil 2%. The most common side effect of minoxidil hair loss treatment is the scalp irritation and redness. All current minoxidil commercial formulations are made with alcohol-based agents as a media to maintain a stable composition, being propylene glycol the basic ingredient of these formulations. Propylene glycol is the main cause for scalp irritation and redness. In addition, minoxidil hair loss treatment side effects also include having greasy hair that may also be sticky and are hard to manage. Propylene glycol is also the reason for this wet appearance and oily and sticky to the touch. Minoxidil needs to be applied twice daily and must be used indefinitely for continued support of existing hair follicles and the maintenance of any experienced hair regrowth. Thus, for successful long-term use it is important to avoid uncomfortable side effects and allow a pleasant use on the cosmetic level. PRODUCT DESCRIPTION Bionanoplus propylene glycol free minoxidil formulation is a hydroalcoholic solution with low viscosity suitable for topical use in which all the excipients are approved by the international regulatory agencies for human topical use. The exact composition of the formulation is showed in the table below. % Minoxidil (w/v) % Gantrez ES (w/v) % Ethanol (v/v) % Carrier (v/v)* % Water (v/v) 2 or Q.S.100 *Information available under a confidential disclosure agreement.
3 Page 3 of 7 The formulation can be easily and cost-effective produced at a commercial scale with standard processes of solution preparation. Bionanoplus has scale-up the process from 250 ml to 2 L without any significant technical issue. BIONANOPLUS MINOXIDIL FORMULATION IS PROPYLENE GLYCOL FREE AND STABLE AT ROOM TEMPERATURE Bionanoplus minoxidil formulation does not contain any propylene glycol and is stable for at least one year at room temperature in transparent glass vials. Initial Point 6 Months 12 Months Minoxidil Content (% by HPLC) Macroscopical characteristics* 5.1 ± ± ±0.1 Transp. No pp. CL Transp. No pp. SYC Transp. No pp. SYC * Transp= Transparent; No pp = No precipitation; CL= colorless; SYC= Slight yellow color. This propylene glycol free minoxidil formulation doesn t produce any scalp irritation and is significantly less oily and sticky than current commercial formulations. Therefore, Bionanoplus formulation presents both, a safety profile and cosmetic level which constitutes an unquestionable advantage for the patient using long-term treatment. NO RESIDUAL CRYSTALLINE PRECIPITATE POST SOLVENT EVAPORATION COMPARED TO COMMERCIAL PRODUCTS Minoxidil is somewhat soluble in both propylene glycol and alcohol, but nearly insoluble in water. Commercial formulations are supersaturated propylene glycol/minoxidil solutions that even tend to precipitate out some of the minoxidil at room temperature. Propylene glycol of commercial products evaporates after application and minoxidil precipitates on the scalp producing an unaesthetic dandruff effect and enhancing
4 Page 4 of 7 irritation. In contrast, Bionanoplus formulation doesn t precipitate in a crystalline form after application and evaporation of the solvent. Figure 1: Comparison of crystalline precipitation of minoxidil in pork skin post solvent evaporation between Bionanoplus formulation and commercial products. A) Observation of minoxidil 5% formulations by optical microscopy. B) Observation of minoxidil 2% formulations by scanning electron microscopy. SYSTEMIC EXPOSURE OF MINOXIDIL AFTER TOPICAL ADMINISTRATION IS NOT HIGHER THAN COMMERCIAL PRODUCTS THEREFORE NO SYSTEMIC EFFECTS ARE EXPECTED In the 1970s Minoxidil was a drug used to treat hypertension, classified as a potassium channel opener with effects on expansion of peripheral vascular. For this reason, another minoxidil topical administration treatment side effect is changes in the blood pressure and, consequently, minoxidil absorption into the blood after topical administration must be as low as possible. Despite its higher skin residence time, Bionanoplus minoxidil absorption into the blood after its topical administration is
5 Page 5 of 7 bioequivalent to commercial products and, in consequence, shows a consistent safety profile. Figure 2: Comparison of minoxidil absorption into the blood over 24 hours. Penetration of minoxidil through the epidermis was evaluated in Franz diffusion cells using fresh pork ear skin. The absorption grade was evaluated measuring minoxidil levels in the receptor compartment (similar to blood) over a 24 hours period. LACOVIN (Galderma) is a standard formulation of minoxidil with propylene glycol. ALOPEXY (Pierre Fabre) is a formulation with gamma-cyclodextrin which enhances the solubility of minoxidil in water and decreases the requirement for propylene glycol. REGULATORY AFFAIRS The legal basis for submission of a marketing-authorization of the Bionanoplus minoxidil formulation is the approved reference listed drugs which contains minoxidil for topic use. Bionanoplus minoxidil formulation is a hydroalcoholic solution for topical application with non-active ingredients that differ from the reference listed drug product, thus the regulation specifies that this difference must be characterized and it has to be provided
6 Page 6 of 7 information demonstrating that do not affect the safety or efficacy of the proposed drug product. According to the different international regulatory agencies, there are two options to provide this information: 1. Results from an in vivo bioequivalence study. 2. A waiver of the in vivo bioequivalence study supported with expert justifications and/or data from in vitro assays. Bionanoplus believes that it is not necessary to obtain clinical data and that the second option would be easier and faster because: 1. The formulation has the same active ingredient in the same concentration and dosage form as the reference listed drug product. 2. There is a considerable knowledge about the efficacy and safety of the active substance collected during more than thirty years of topic use for the treatment of hair loss. 3. All the non-active ingredients are approved by the international regulatory agencies for human topical use and are currently present as common excipients in many pharmaceuticals. 4. Minoxidil is a locally acting product that exerts its effect at the site of application. As in this case, a change in non-active ingredients may influence the safety of the product modifying the penetration of the active, thus this effect needs to be carefully investigated. For locally acting well-known active substances as minoxidil, the international regulatory agencies do not consider necessary full toxicological and clinical data if it is not expected that the amount of active ingredient reaching the systemic circulation is higher than for the original product. An in vitro assay in Franz diffusion cells has shown that Bionanoplus minoxidil absorption into the blood after its topical administration is bioequivalent to the reference listed drug product and, therefore, it is not necessary to obtain clinical data. In any case, before submission of a marketing-authorization, it is recommended to request scientific advice from the corresponding regulatory agency.
7 Page 7 of 7 INTELLECTUAL PROPERTY STATUS AND PARTNERSHIP CONDICTIONS Bionanoplus holds the intellectual property rights of this propylene glycol free Minoxidil topical formulation worldwide in the patent PCT/EP2012/ (priority date 15/04/2011). The second written opinion of the International Preliminary Examining Authority (April 2013) has established novelty, inventive step and industrial applicability in all the key claims. Bionanoplus seeks to license the further development and commercialization of its minoxidil formulation for hair lost treatment. The ideal partner would be: A company with a strong therapeutic focus in the dermatology market. Willing to commit investment to develop the product worldwide. Marketing experience with capacity to put on the market place the product directly or through alliances. Bionanoplus is open to different format of partnering modalities including: Worldwide exclusive licensing. Country based exclusive licensing. Opt-in rights + research fee. CONTACT DETAILS Hesham Salman CEO hsalman@bionanoplus.com Ricardo Palacios Business Development Manager rpalacios@bionanoplus.com
Scientific Discussion post-authorisation update for Rheumocam extension X/007
5 May 2011 EMA/170257/2011 Veterinary Medicines and Product Data Management Scientific Discussion post-authorisation update for Rheumocam extension X/007 Scope of extension: addition of 20 mg/ml solution
More informationUnited Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE
United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Advantage
More informationIrish Medicines Board
Irish Medicines Board (Reference Member State) DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Pestigon 50 mg Spot-On Solution for Cats Pestigon vet 50 mg
More informationHOW XTC IMPROVED MINOXIDIL PENETRATION - 5 WAYS!
HOW XTC IMPROVED MINOXIDIL PENETRATION - 5 WAYS! What Hinders Minoxidil from Working Well 1. Sebum from sebaceous gland blocks the hair follicle. 2. Minoxidil therefore, cannot penetrate through the sebum
More informationFRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS La Haute Marche Javené BP FOUGERES cedex FRANCE
FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS La Haute Marche Javené BP 90203 35302 FOUGERES cedex FRANCE DECENTRALISED PROCEDURE FOR A VETERINARY MEDICINAL PRODUCT Zodon 25 mg/ml oral solution for cats
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion SE/H/1397/01-05/DC Ramipril/Amlodipine Sandoz (ramipril/amlodipine) Applicant: Sandoz A/S This module reflects the scientific discussion for the approval
More informationOIE Conference on Veterinary Medicinal Products in the Middle East
OIE Conference on Veterinary Medicinal Products in the Middle East Damascus, Syria, 2-4 December 2009 International Approach for Veterinary Medicinal Products: VICH Barbara Freischem, IFAH Overview Regulatory
More informationIrish Medicines Board
Irish Medicines Board (Reference Member State) DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Zeronil 50 mg Spot-on Solution for cats CMD(v)/TEM/003-00
More informationAmoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate
Annex I List of the names, pharmaceutical form, strength of the veterinary medicinal product, animal species, route of administration, applicant in the Member States Member State EU/EEA Applicant Name
More informationIrish Medicines Board
Irish Medicines Board (Reference Member State) DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Zeronil 402 mg Spot-on Solution for extra large dogs CMD(v)/TEM/003-00
More informationAll medicinal products (for human and veterinary use) are regulated under the single Pharmaceutical Act.
1 2 All medicinal products (for human and veterinary use) are regulated under the single Pharmaceutical Act. The Act and the subsequent Cabinet Ordinance provide higher rules applicable for both human
More informationKirkland Signature Minoxidil Topical Solution USP, 5% Drug Facts
Kirkland Signature Minoxidil Topical Solution USP, 5% Drug Facts Active ingredient Minoxidil 5% w/v Purpose Hair regrowth treatment for men Use to regrow hair on the top of the scalp (vertex only, see
More informationPackage leaflet: Information for the user
Text draft from 12.07.2018 Minoxidil BIO-H-TIN-Pharma 20 mg/ml Page 1 Package leaflet: Information for the user Minoxidil BIO-H-TIN-Pharma 20 mg/ml cutaneous spray, solution Minoxidil For women aged over
More informationAnatara Investor Presentation
ASX Release Anatara Investor Presentation BRISBANE, 21st June 2017: Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation for the Gold Coast Investment Showcase (June
More informationHEADWAY 2.0% TOPICAL SOLUTION
HEADWAY 2.0% TOPICAL SOLUTION Minoxidil 2.0% Topical Solution Submission for Reclassification October 2001 MINOXIDIL 2.0% TOPICAL SOLUTION Submission for Reclassification Page 2 BACKGROUND TO THE SUBMISSION...
More informationPublic Assessment Report. Scientific discussion. Xiflodrop 5 mg/ml eye drops, solution. Moxifloxacin hydrochloride DK/H/2221/001/DC
Public Assessment Report Scientific discussion Xiflodrop 5 mg/ml eye drops, solution Moxifloxacin hydrochloride DK/H/2221/001/DC This module reflects the scientific discussion for the approval of Xiflodrop.
More informationApproved by the Food Safety Commission on September 30, 2004
Approved by the Food Safety Commission on September 30, 2004 Assessment guideline for the Effect of Food on Human Health Regarding Antimicrobial- Resistant Bacteria Selected by Antimicrobial Use in Food
More informationMoxifloxacin (as hydrochloride) 400 mg Tablets WHOPAR part 6 November 2017 (Hetero Labs Limited), TB 315
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationAssessment of compliance of current legislation: Veterinary Products Act
of compliance of current legislation: Veterinary Products Act Dr Stuart A. Slorach Chairman, OIE Animal Production Food Safety Working Group Training seminar on veterinary legislation, Gaborone, 2011 1
More informationJaipur Declaration on Antimicrobial Resistance
Jaipur Declaration on Antimicrobial Resistance We, the Health Ministers of Member States of the WHO South-East Asia Region participating in the Twenty-ninth Health Ministers Meeting in Jaipur, India, appreciate
More informationCOUNCIL REGULATION (EEC) No 2377/90
-W- -- 18. 8. 90 Official Journal of the ~uroiean Communities No L 224/P - - (Acts whose publication is obligatory) COUNCIL REGULATION (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure
More informationMUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT
Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) Federal Office of Consumer Protection and Food Safety Mauerstraße 39-42 10117 Berlin (Germany) MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE
More informationVeterinary Drugs Stakeholder Forum Meeting 1 - Summary
Veterinary Drugs Stakeholder Forum Meeting 1 - Summary Sanja Modric, D.V.M., Ph.D., Chair j,,, FDA Center for Veterinary Medicine Wrap Up Session Friday, November 9, 2012 Organization Overviews FDA Center
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
1 2 3 18 October 2013 EMEA/CVMP/EWP/141272/2011 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in cattle
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Fiprex CAT 52.5 mg spot-on solution for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One pipette (0.7 ml) contains:
More informationVICH:Organization,Guidelines and Global Outreach
VICH:Organization,Guidelines and Global Outreach Bettye K. Walters, DVM International Programs Bettye.walters@fda.hhs.gov Merton V. Smith, Ph.D., J.D. Director, International Programs Center for Veterinary
More informationDr Elisabeth Erlacher Vindel Head of Science and New Technologies Departement OIE AMR strategy and activities related to animal health
Dr Elisabeth Erlacher Vindel Head of Science and New Technologies Departement OIE AMR strategy and activities related to animal health Regional Workshop for National Focal Points for Veterinary Products
More informationScientific discussion
21 February 2011 EMA/CVMP/510016/2010 Veterinary Medicines and Product Data Management This module reflects the initial scientific discussion for the approval of Melosus (as published in February 2011).
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
1 2 3 18 February 2016 CVMP/344/1999-Rev.2 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in Draft Draft
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
19 January 2017 EMA/CVMP/344/1999-Rev.2 Committee for Medicinal products for Veterinary Use Guideline on the conduct of efficacy studies for intramammary products for use in cattle Draft agreed by Efficacy
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationUse to regrow hair on the top of the scalp (vertex only, see pictures on side of this carton)
Kirkland Signature Minoxidil Topical Aerosol, 5% (Foam) Drug Facts Active ingredient Minoxidil 5% w/w (without propellant) Purpose Hair regrowth treatment for men Use to regrow hair on the top of the scalp
More informationReview of Legislation for Veterinary Medicinal Products Version 2
Position Paper Brussels, 13 April 2012 Review of Legislation for Veterinary Medicinal Products Version 2 Directive 2004/28 entered into force on 1 st May 2004, introducing many improvements for the transparent
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Euthasol vet. 400 mg/ml, solution for injection (AT, BE, DK, EE, EL, FI, IE, IS, LT, LU, LV, NO, PL, RO SE, UK)
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Euthasol vet. 400 mg/ml, solution for injection (AT, BE, DK, EE, EL, FI, IE, IS, LT, LU, LV, NO, PL, RO SE, UK) Euthasol 400
More informationAntimicrobial Resistance Direction Statement for Animals and Plants, and Work Programme
Antimicrobial Resistance Direction Statement for Animals and Plants, and Work Programme MPI Discussion Paper No: 2016/10 ISBN No: 978-1-77665-185-0 (online) ISSN No: 2253-3907 (online) February 2016 Disclaimer
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BTVPUR AlSap 1 suspension for injection for sheep and cattle. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose
More informationFREEDOM OF INFORMATION (FOI) SUMMARY
Date of Approval: March 25, 2003 FREEDOM OF INFORMATION (FOI) SUMMARY Acepromazine Maleate Injection 10 mg/ml Tranquilizer for use in dogs, cats, and horses ANADA 200-319 Phoenix Scientific, Inc. 3915
More informationCommittee for Medicinal Products for Veterinary Use (CVMP) Work Plan 2018
7 December 2017 Committee for Medicinal Products for Veterinary Use (CVMP) Committee for Medicinal Products for Veterinary Use (CVMP) Work Plan 2018 Chairpersons Chair: D. Murphy Status Adopted in December
More informationGuidance for Industry
Guidance for Industry #213 New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food- Producing Animals: Recommendations for Drug Sponsors
More informationDr. Gérard Moulin AFSSA/ANMV OIE Collaborating Centre on Veterinary medicinal products BP FOUGERES CEDEX, FRANCE
Dr. Gérard Moulin AFSSA/ANMV OIE Collaborating Centre on Veterinary medicinal products BP 90203-35302 FOUGERES CEDEX, FRANCE gerard.moulin@anses.fr Introduction to the working sessions Need for a good
More informationTHE IMPORTANCE OF QUALITY IN COMPOUNDED VETERINARY MEDICINES
THE IMPORTANCE OF QUALITY IN COMPOUNDED VETERINARY MEDICINES GOOD MANUFACTURING PRACTICES On the 12th of June 2015 Bova was the first pharmacy in Australia to be granted a licence to manufacture veterinary
More informationCenter for Veterinary
Center for Veterinary Medicine: Overview Sanja Modric, DVM, PhD Office of New Animal Drug Evaluation Center for Veterinary Medicine i Food and Drug Administration USP Veterinary Stakeholder Forum, 11-09-2012
More informationCombating Antimicrobial Resistance: A Manufacturing Perspective
Combating Antimicrobial Resistance: A Manufacturing Perspective Steve Brooks VP, EHS Pfizer Inc & Chair, Environmental Work Group of the AMR Industry Alliance June 20 th 2017 AMR - Environmental Matters
More informationBeef Producers. The Judicious Use of Antimicrobials for
The Judicious Use of Antimicrobials for Beef Producers Introduction The production of safe and wholesome animal products for human consumption is a primary goal of beef producers. To achieve that goal,
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION 1. SUMMARY OF THE DOSSIER Rheumocam is a generic medicinal product as defined in Article 13(2) (b) of Directive 2001/82/EC, as amended by Directive 2004/28/EC. The reference veterinary
More informationLegislation, Registration and Control Procedures for Veterinary Medicinal Products in the European Union
Legislation, Registration and Control Procedures for Veterinary Medicinal Products in the European Union David Mackay European Medicines Agency (EMEA) London, UK Legal Framework Medicines control within
More informationPhysician Veterinarian Do you have the Bayer Spirit?
CropScience HealthCare MaterialScience Business Services Industry Services Technology Services www.mybayerjob.com Physician Veterinarian Do you have the Bayer Spirit? Research and Development, Occupational
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS VIRBAGEN OMEGA - EN 1
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS VIRBAGEN OMEGA - EN 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Virbagen Omega 5 MU for dogs Virbagen Omega 10 MU for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationGuidance for Industry
Guidance for Industry #213 New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food- Producing Animals: Recommendations for Drug Sponsors
More informationResolution adopted by the General Assembly on 5 October [without reference to a Main Committee (A/71/L.2)]
United Nations A/RES/71/3 General Assembly Distr.: General 19 October 2016 Seventy-first session Agenda item 127 Resolution adopted by the General Assembly on 5 October 2016 [without reference to a Main
More informationEuropean Regional Verification Commission for Measles and Rubella Elimination (RVC) TERMS OF REFERENCE. 6 December 2011
European Regional Verification Commission for Measles and Rubella Elimination (RVC) TERMS OF REFERENCE 6 December 2011 Address requests about publications of the WHO Regional Office for Europe to: Publications
More informationPersonal Protection: Topical Repellents
Personal Protection: Topical Repellents Susan Jennings Senior Public Health Advisor Office of Pesticide Programs US Environmental Protection Agency May 16, 2016 Topical Repellents and IPM Repellents are
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nuzyra) Reference Number: CP.PMN.## Effective Date: 11.20.18 Last Review Date: 02.19 Line of Business: Commercial, TBD HIM*, Medicaid Coding Implications Revision Log See Important Reminder
More informationSUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NUFLOR 300 mg/ml solution for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/18
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/18 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Oncept IL-2 lyophilisate and solvent for suspension for injection for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationSUMMARY OF PRODUCT CHARACTERSITICS
SUMMARY OF PRODUCT CHARACTERSITICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eliminall 2.5 mg/ml cutaneous spray, solution for cats and dogs Exproline vet 2.5 mg/ml cutaneous spray, solution for cats
More informationAgencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)
DEPARTAMENTO DE MEDICAMENTOS VETERINARIOS Medicamentos y Productos C/Campezo 1, Edificio 8 28022 Madrid España (Reference Member State) DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR
More informationThe purpose of this call is to support the development of innovative veterinary solutions to reduce the use of antibiotics in food-producing animals
Global Call for Research Proposals: Innovative Veterinary Solutions for Antimicrobial Resistance (InnoVet-AMR) in Food-Producing animals: Livestock and Aquaculture This document is a Call for Research
More informationQuality of Veterinary Medicinal Products. How to ensure the quality of Veterinary Medicinal Products
Quality of Veterinary Medicinal Products How to ensure the quality of Veterinary Medicinal Products Gérard Moulin Anses/ANMV OIE Collaborating Centre on Veterinary medicinal products gerard.moulin@anses.fr
More informationCollege ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board. Graadt van Roggenweg AH Utrecht The Netherlands
College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board Graadt van Roggenweg 500 3531 AH Utrecht The Netherlands MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A
More informationRecognition of Export Controls and Certification Systems for Animals and Animal Products. Guidance for Competent Authorities of Exporting Countries
Recognition of Export Controls and Certification Systems for Animals and Animal Products Guidance for Competent Authorities of Exporting Countries Disclaimer This guidance does not constitute, and should
More informationAmerican Veterinary Medical Association
AVMA American Veterinary Medical Association Governmental Relations Division 1910 Sunderland Place, NW Washington, DC 20036-1642 phone 202.789.0007 800.321.1473 fax 202.842.4360 AVMA Headquarters 1931
More informationTHIS PATIENT GROUP DIRECTION HAS BEEN APPROVED on behalf of NHS Fife by:
Patient Group Direction for Named Community Pharmacists to Supply CHLORAMPHENICOL EYE DROPS 0.5% To patients aged 1 year and older Under the Minor Ailments Service. Number 114 Issued October 2016 Issue
More informationLABELLING AND PACKAGE LEAFLET
LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE CARTON BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MILTEFORAN 20 mg/ml oral solution for dogs miltefosine 2.
More informationThe Future of Antibiotic Alternatives
The Future of Antibiotic Alternatives @Elanco #feedthe9 Grady Bishop Sr. Director Market Access Elanco 1 The Global Landscape our WHY 2 Today s 3 Food Security Realities 3 The Protein Gap 4 The impact
More informationOIE strategy on AMR and the Prudent Use of Antimicrobials
Dr. Jocelyn Mérot OIE Sub-Regional Representation for North Africa OIE strategy on AMR and the Prudent Use of Antimicrobials 14th JPC REMESA 19-20 July 2017 Naples (Italy) The OIE Strategy on AMR and the
More informationPublic Assessment Report Scientific discussion. Perindopril tert-butylamine/amlodipine Stada (perindopril and amlodipine) SE/H/1500/01-04/DC
Public Assessment Report Scientific discussion Perindopril tert-butylamine/amlodipine Stada (perindopril and amlodipine) SE/H/1500/01-04/DC This module reflects the scientific discussion for the approval
More informationPrivate Sector Perspectives IFAH (worldwide)
OIE National Focal Points for Veterinary Products training Johannesburg, SouthAfrica, 23 26 November2010 Private Sector Perspectives IFAH (worldwide) Barbara Freischem IFAH, Executive Director Presentation
More informationGlobal Strategies to Address AMR Carmem Lúcia Pessoa-Silva, MD, PhD Antimicrobial Resistance Secretariat
Global Strategies to Address AMR Carmem Lúcia Pessoa-Silva, MD, PhD Antimicrobial Resistance Secretariat EMA Working Parties with Patients and Consumers Organisations (PCWP) and Healthcare Professionals
More informationEvaluation of the hair growth and retention activity of two solutions on human hair explants
activity of two solutions on human hair explants Study Directed by Dr E. Lati of Laboratoire Bio-EC, Centre de Recherches Biologiques et d Experimentations Cutanees, on behalf of Pangaea Laboratories Ltd.
More informationPfizer Position on Antimicrobial Resistance Management. Kirill Tverskoy, Medical Director Pfizer Russia February 21, 2017
Pfizer Position on Antimicrobial Resistance Management Kirill Tverskoy, Medical Director Pfizer Russia February 21, 2017 Objectives and Trends of Nowadays Healthcare Environment Effective and innovative
More information2017 Disruptive Growth Company Showcase NYC September 27, 2017
2017 Disruptive Growth Company Showcase NYC September 27, 2017 Disclaimer These materials have been prepared for informational purposes only in relation to Zomedica and are not, under any circumstances,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Advantage 40 Spot-on solution for Cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Imidacloprid 40 mg/pipette
More informationUniversity of Illinois at Springfield. Policies and Procedures Governing Care and Use of Laboratory Animals in Research and Teaching
University of Illinois at Springfield Policies and Procedures Governing Care and Use of Laboratory Animals in Research and Teaching Federal regulations require each institution using vertebrate animals
More informationHerbal Medicine for Animal Use in JAPAN
Herbal Medicine for Animal Use in JAPAN Quality Assay Section, Assay Division Ⅱ, National Veterinary Assay Laboratory 21 Dec. 2016 6 Oct. 2016 1 Veterinary Drugs Veterinary Drugs Veterinary Pharmaceuticals
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican Herpes 205 powder and solvent for emulsion for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active
More informationANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS
ANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS PHM025D March 2016 Neha Maliwal Project Analyst ISBN: 1-62296-252-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationStandard operating procedure
Standard operating procedure Title: Annual review of VeDDRA list to be used in EudraVigilance Veterinary Status: PUBLIC Document no.: SOP/V/4019 Lead author Approver Effective date: 15-MAY-15 Name: Raquel
More informationUnited Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE
United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Clavudale
More informationHair plus back Foam 5% w/w Minoxidil
SPC Hair plus back Foam 5% w/w Minoxidil Table of Contents 1. Name of the medicinal product 2. Qualitative and quantitative composition 3. Pharmaceutical form 4. Clinical particulars 4.1 Therapeutic indications
More informationInternational Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.
I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Purevax RCPCh lyophilisate and solvent for suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationUnited Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE
United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT (AT, BE,
More informationVeterinary. Kevin Oberlander, RPh Deborah Clark, RPh Chris Simmons, RPh International Seminar Houston, TX November 10 12, 2016
Veterinary Kevin Oberlander, RPh Deborah Clark, RPh Chris Simmons, RPh International Seminar Houston, TX November 10 12, 2016 2016. All Rights Reserved. 1 Building Relationships with Veterinarians Kevin
More informationOIE Resolution and activities related to the Global Action Plan. Regional Seminar for OIE National Focal Points for Veterinary Products 4 th Cycle
Dr Elisabeth Erlacher Vindel Deputy Head of the Scientific and Technical Departement World Organisation for Animal Health (OIE) OIE Resolution and activities related to the Global Action Plan Regional
More informationTERMS AND CONDITIONS
TERMS AND CONDITIONS Publish Date: 27th March 2018 The following terms and conditions ( Terms and Conditions ) apply to the provision by Guide Dogs Association of SA & NT Inc. (ABN 91 183 168 093) trading
More informationRegulatory Framework for the Availability and Use of Animal Drugs in the United States
Regulatory Framework for the Availability and Use of Animal Drugs in the United States Sanja Modric, DVM, PhD KEYWORDS Drug approval process Approved versus unapproved drugs Regulatory Safety KEY POINTS
More informationLABELLING AND PACKAGE LEAFLET A. LABELLING
LABELLING AND PACKAGE LEAFLET A. LABELLING DATA TO BE MARKED ON THE EXTERIOR OF THE PACKAGING DATA TO BE MARKED ON THE DIRECT PACKAGING DESCRIPTION AND TYPE OF THE PACKAGING 1. NAME OF THE VETERINARY MEDICAL
More informationCanada s Activities in Combatting Antimicrobial Resistance. Presentation to the JPIAMR Management Board March 29, 2017
Canada s Activities in Combatting Antimicrobial Resistance Presentation to the JPIAMR Management Board March 29, 2017 AMR in Canada Surveillance data indicates that rates of infection for some resistant
More informationProviding Diagnostics to the International Veterinary Community
Providing Diagnostics to the International Veterinary Community MISSION The Texas A&M Veterinary Medical Diagnostic Laboratory (TVMDL) looks to engage entities in Latin America who share a common interest
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Fiprex S 75 mg spot-on solution for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One pipette (1 ml) contains: Active
More informationProposed New Brighton Park Shoreline Habitat Restoration Project
Prepared by Kirk & Co. Consulting Ltd. Port Metro Vancouver and Vancouver Board of Parks and Recreation Proposed New Brighton Park Shoreline Habitat Restoration Project Public Engagement Regarding Dog
More informationBOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin
BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES Each ml contains: Tilmicosin 300 mg;
More informationADVANTAGE FOR CATS
ADVANTAGE FOR CATS For use on cats only. Do not use on dogs or rabbits. For use on kittens and cats from 8 weeks of age. INDICATION A fast action, monthly spot-on flea treatment. Kills 98-100% adult fleas
More informationFollow this and additional works at: Part of the Skin and Connective Tissue Diseases Commons
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Minoxidil Efficacious and Safe for
More informationThe Philippine Action Plan to Combat Antimicrobial Resistance: One Health Approach
The Philippine Action Plan to Combat Antimicrobial Resistance: One Health Approach Prese ted at the Workshop o Natio al A tio Plan on Antimicrobial Resistance for Developing Countries Focusing on Resistance
More informationPork Production: A Nexus of Farming, Food and Public Health
Pork Production: A Nexus of Farming, Food and Public Health Jennifer Koeman, DVM, MSc, MPH, DACVPM Director, Producer and Public Health National Pork Board Antibiotic Use Guidance for U.S. Pork Producers
More informationGuideline on quality data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market
8 December 2016 EMA/CVMP/QWP/128710/2004-Rev.1 Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on quality data requirements for veterinary medicinal products intended for minor use
More information